Science Explorer Back to mapMap
Institution · Innovaderm (Canada)

Most cited papers from Innovaderm (Canada)

What are the most cited papers from Innovaderm (Canada)?

The most cited paper from Innovaderm (Canada) is "The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis" (C. Roubille, Vincent Richer, Tara Starnino et al., 2015), with 908 citations. Next come "Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis" (701) and "Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus" (662).

Showing 50 of 61 papers. Every paper with more than 94 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis C. Roubille, Vincent Richer, Tara Starnino et al. · Annals of the Rheumatic Diseases ReviewOpen access 6 Jan 2015 908
2 Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis Emma Guttman‐Yassky, Robert Bissonnette, Benjamin Ungar et al. · Journal of Allergy and Clinical Immunology Open access 5 Sep 2018 701
3 Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: An international consensus Lasse Roger Braathen, Rolf‐Markus Szeimies, Nicole Basset‐Séguin et al. · Journal of the American Academy of Dermatology 25 Dec 2006 662
4 Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial Eric Lawrence Simpson, Rodney Daniel Sinclair, Seth B. Forman et al. · The Lancet Open access Jul 2020 516
5 A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis Kim Alexander Papp, Kristian Reich, Carle F. Paul et al. · British Journal of Dermatology Open access 25 Feb 2016 470
6 Topical tofacitinib for atopic dermatitis: a phase II a randomized trial Robert Bissonnette, Kim Alexander Papp, Yves P. Poulin et al. · British Journal of Dermatology Open access 16 Jul 2016 422
7 Efficacy and safety of oral alitretinoin (9-cis retinoic acid) in patients with severe chronic hand eczema refractory to topical corticosteroids: results of a randomized, double-blind, placebo-controlled, multicentre trial Thomas Ruzicka, Charles W Lynde, Gregor B. E. Jemec et al. · British Journal of Dermatology 21 Feb 2008 412
8 Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials Eric Lawrence Simpson et al. · British Journal of Dermatology 30 Jan 2020 391
9 Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council Yael Renert‐Yuval, Jacob Pontoppidan Thyssen, Robert Bissonnette et al. · Journal of Allergy and Clinical Immunology Open access 28 Jan 2021 349
10 A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis Kenneth B. Gordon, Kristina Callis Duffin, Robert Bissonnette et al. · New England Journal of Medicine Open access 8 Jul 2015 305
11 A MicroRNA-29 Mimic (Remlarsen) Represses Extracellular Matrix Expression and Fibroplasia in the Skin Corrie L. Gallant‐Behm, Joseph Piper, Joshua M. Lynch et al. · Journal of Investigative Dermatology Open access 22 Nov 2018 288
12 Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study Mette Sondergaard Deleuran et al. · Journal of the American Academy of Dermatology Open access 30 Jul 2019 259
13 Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis Melinda Gooderham, Seth B. Forman, Robert Bissonnette et al. · JAMA Dermatology Open access 2 Oct 2019 244
14 IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis Chris Callewaert, Teruaki Nakatsuji, Rob Knight et al. · Journal of Investigative Dermatology Open access 25 Jun 2019 226
15 GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis Emma Guttman‐Yassky, Ana Brânduşa Pavel, Lisa Ya Zhou et al. · Journal of Allergy and Clinical Immunology Open access 7 Feb 2019 226
16 Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis Helen Mengze He, Robert Bissonnette, Jianni Wu et al. · Journal of Allergy and Clinical Immunology 21 Jul 2020 225
17 Daylight photodynamic therapy for actinic keratosis: an international consensus Stine Regin Wiegell, Hans Christian Wulf, Rolf‐Markus Szeimies et al. · Journal of the European Academy of Dermatology and Venereology 23 Dec 2011 219
18 Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis Margitta Worm et al. · JAMA Dermatology Open access 26 Dec 2019 215
19 Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study Alexa B. Kimball, Kim Alexander Papp, Yasmine S. Wasfi et al. · Journal of the European Academy of Dermatology and Venereology Open access 20 Dec 2012 214
20 Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL ‐17A inhibition in psoriasis Kristian Reich et al. · Experimental Dermatology Open access 2 Apr 2015 211
21 Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis Eric Lawrence Simpson, Kim Alexander Papp, Andrew Blauvelt et al. · JAMA Dermatology Open access 9 Mar 2022 209
22 A randomized phase 2a efficacy and safety trial of the topical J anus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis W.C. Ports, Sairah M. Khan, Shu-Ping Lan et al. · British Journal of Dermatology Open access 6 Feb 2013 204
23 Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment ( SCULPTURE Extension Study) Robert Bissonnette, Thomas Anton Luger, Diamant Thaçi et al. · Journal of the European Academy of Dermatology and Venereology Open access 14 Feb 2018 200
24 Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis Mark Lebwohl, Linda Stein Gold, Bruce E Strober et al. · New England Journal of Medicine 8 Dec 2021 194
25 Human mast cells are major IL-22 producers in patients with psoriasis and atopic dermatitis Shunya Mashiko, Salim Bouguermouh, Manuel Rubio et al. · Journal of Allergy and Clinical Immunology 16 Mar 2015 187
26 The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis Eric Lawrence Simpson et al. · Journal of the American Academy of Dermatology 27 Apr 2020 185
27 Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent Robert Bissonnette, Linda Stein Gold, David S. Rubenstein et al. · Journal of the American Academy of Dermatology Open access 3 Nov 2020 184
28 A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial Andrew Blauvelt et al. · British Journal of Dermatology Open access144 authors 30 Dec 2019 176
29 A New Calcipotriol/Betamethasone Dipropionate Formulation (DaivobetTM) Is an Effective Once-Daily Treatment for Psoriasis vulgaris Roland Kaufmann, Adrian Bibby, Robert Bissonnette et al. · Dermatology 2002 164
30 Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies Marjolein S. de Bruin-Weller, Tilo M. Biedermann, Robert Bissonnette et al. · Acta Dermato Venereologica Open access 2021 150
31 Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial Robert Bissonnette, Lars Iversen, Howard L. Sofen et al. · British Journal of Dermatology 21 Nov 2014 149
32 Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials Thomas R.M. Bieber, Jacob Pontoppidan Thyssen, Kristian Reich et al. · Journal of the European Academy of Dermatology and Venereology Open access 18 Sep 2020 148
33 Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis Ana Brânduşa Pavel, Teresa Song, Hyun Je Kim et al. · Journal of Allergy and Clinical Immunology 26 Jul 2019 146
34 Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5) Eric Lawrence Simpson, Seth B. Forman, Jonathan I. Silverberg et al. · Journal of the American Academy of Dermatology Open access 17 Feb 2021 138
35 Feasibility Analysis of a Novel Cell Equalizer Topology for Plug-In Hybrid Electric Vehicle Energy-Storage Systems Pablo A. Cassani, Sheldon S. Williamson · IEEE Transactions on Vehicular Technology 9 Sep 2009 138
36 Differential Changes in Inflammatory Mononuclear Phagocyte and T-Cell Profiles within Psoriatic Skin during Treatment with Guselkumab vs. Secukinumab Heena Mehta, Shunya Mashiko, Julianty Angsana et al. · Journal of Investigative Dermatology Open access 30 Jan 2021 136
37 Socioeconomic Burden of Immune-Mediated Inflammatory Diseases -- Focusing on Work Productivity and Disability Philip Jacobs, Robert Bissonnette, Lyn Guenther · Journal of Rheumatology Supplement Open access Nov 2011 135
38 Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis Lisa A. Beck, Diamant Thaçi, Mette Sondergaard Deleuran et al. · American Journal of Clinical Dermatology Open access 17 Jun 2020 134
39 Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data Bruce E Strober, Craig L. Leonardi, Kim Alexander Papp et al. · Journal of the American Academy of Dermatology Open access 23 Nov 2016 131
40 Increased expression of IL ‐17A and limited involvement of IL ‐23 in patients with palmo‐plantar ( PP ) pustular psoriasis or PP pustulosis; results from a randomised controlled trial Robert Bissonnette, Simon Nigen, Richard G B Langley et al. · Journal of the European Academy of Dermatology and Venereology 24 Sep 2013 131
41 The oral Janus kinase/spleen tyrosine kinase inhibitor ASN 002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermatitis: results from a randomized double‐blind placebo‐controlled study Robert Bissonnette, Catherine Maari, Seth B. Forman et al. · British Journal of Dermatology Open access 28 Mar 2019 130
42 Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial Robert Bissonnette, Ana Brânduşa Pavel, Aisleen Diaz et al. · Journal of Allergy and Clinical Immunology Open access 13 Aug 2019 129
43 Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis Caitriona Ryan et al. · British Journal of Dermatology Open access 10 May 2018 126
44 Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies Kim Alexander Papp, Boulos Paul Haraoui, Deepali Kumar et al. · Journal of Cutaneous Medicine and Surgery Open access 21 Nov 2018 125
45 Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis Evgeny V. Berdyshev, Elena Goleva, Robert Bissonnette et al. · Allergy Open access 11 Jul 2022 115
46 ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation Juan Manuel Leyva-Castillo, C Galand, Shunya Mashiko et al. · Journal of Allergy and Clinical Immunology Open access 14 Mar 2020 113
47 Increased frequencies of basophils, type 2 innate lymphoid cells and Th2 cells in skin of patients with atopic dermatitis but not psoriasis Shunya Mashiko, Heena Mehta, Robert Bissonnette et al. · Journal of Dermatological Science 15 Jul 2017 108
48 Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis Lisa A. Beck, Mette Sondergaard Deleuran, Robert Bissonnette et al. · American Journal of Clinical Dermatology Open access May 2022 106
49 Successful retreatment with alitretinoin in patients with relapsed chronic hand eczema Robert Bissonnette, Margitta Worm, B. Gerlach et al. · British Journal of Dermatology 10 Nov 2009 105
50 Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review Patrick Joseph Fleming, C. Roubille, Vincent Richer et al. · Journal of the European Academy of Dermatology and Venereology Review 10 Dec 2014 105

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.